Grünenthal and Averitas Pharma Complete Recruitment Phase III Study
Grünenthal and its subsidiary Averitas Pharma are excited to announce the successful completion of recruitment for their pivotal Phase III clinical trial designated as AV001. This trial is set to assess the efficacy of QUTENZA®, a topical treatment for managing post-surgical neuropathic pain (PSNP), which is a common yet often debilitating complication occurring in around 10% of surgical procedures.
The Significance of Post-Surgical Neuropathic Pain
Post-surgical neuropathic pain is increasingly recognized as a significant issue faced by patients who undergo surgery. Approximately 3 million surgeries each year result in this pain, significantly impacting patients' quality of life. The significance of finding effective treatments becomes all the more critical as research indicates that current medication options may not sufficiently address this complication.
QUTENZA®: A Promising Treatment Option
QUTENZA® is a unique non-opioid treatment that utilizes 8% capsaicin in a topical system to offer pain relief for conditions like postherpetic neuralgia and diabetic peripheral neuropathy associated with the feet. Its application offers a non-systemic alternative, providing hope for patients who may struggle with traditional pain medications.
Trial Insights and Future Directions
The AV001 trial is a randomized, double-blind study that includes 410 patients suffering from moderate to severe PSNP for over six months. This extensive study will not only monitor the primary endpoint of pain intensity reduction over a 12-week period but will also evaluate long-term pain management outcomes over 42 weeks. Data from this trial will be crucial in determining future actions, including a potential supplemental new drug application (sNDA) for extended indications in the U.S.
Comments from the Team
Lizandra Marcondes, M.D., PhD, Senior VP of Medical Affairs at Averitas Pharma, expressed optimism regarding QUTENZA® as a viable option for those suffering from post-surgical neuropathic pain, highlighting the importance of addressing unmet medical needs. Marv Kelly, President of Averitas Pharma, echoed this sentiment, emphasizing the milestone reached with recruitment completion and the prospect of fulfilling treatment necessities for a wide patient population.
About QUTENZA® and its Background
The QUTENZA® treatment was first approved for neuropathic pain linked to postherpetic neuralgia, with its label later expanded to include diabetic peripheral neuropathy in 2020. Following its acquisition of U.S. rights in 2018, Grünenthal has committed itself to enhancing patient access and support within the pain management community.
Ongoing Developments in Pain Management
As the trial progresses, expectations for results in late 2025 remain high, specifically aimed at expanding indications to better serve the painful conditions faced by many patients. By incorporating post-surgical neuropathic pain into its label, QUTENZA® could potentially transform pain management strategies, leveraging positive outcomes from the ongoing study.
Conclusion and Future Outlook
The successful recruitment for the AV001 study establishes a significant step forward in Grünenthal's and Averitas Pharma's ongoing mission to improve pain management solutions. The dedicated efforts from both organizations reflect a robust commitment to addressing the challenging landscape of chronic pain and restoring a sense of normalcy in patients' lives.
Frequently Asked Questions
What is the focus of the AV001 clinical trial?
The AV001 trial evaluates the safety and efficacy of QUTENZA® in treating post-surgical neuropathic pain.
Who is involved in the clinical trial?
The trial includes 410 patients who have experienced moderate to severe post-surgical neuropathic pain for at least six months.
What are the expected results timeline for the study?
Topline results from the trial are anticipated in late 2025.
What medications does QUTENZA® provide an alternative to?
QUTENZA® offers a non-opioid alternative for patients who may struggle with traditional systemic pain medications.
How does Grünenthal aim to expand QUTENZA®’s use?
Grünenthal aims to submit a supplemental new drug application to broaden QUTENZA®’s usage in 2026, contingent on positive clinical data.
